Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
GlobalData on MSN7d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...
of 85% from THIO and Libtayo. Vlad Vitoc, CEO of MAIA, said: “Treatment with THIO now shows a 99% probability that OS will extend past chemotherapy’s measure by a wide margin. “THIO’s ...
Libtayo may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) ...
LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer ...
Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your ...
Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback